Sonova Initiates Divestment to Refocus on Core Medical Business

Sonova has commenced a formal sales process for its consumer audio division, marking a strategic reversal nearly four years after acquiring the business from Sennheiser for approximately €200 million. This move represents a significant correction to the company's expansion strategy, which had recently drawn skepticism from the market.

Share Price Nears Annual Low Amid Strategic Shift

The market has reacted negatively to the operational uncertainty surrounding the company in recent months. Sonova's shares closed at €186.85 on Friday, hovering just above their 52-week low of €183.40. Since the start of the year, the stock has declined by more than 17 percent.

Financially, the consequences are already being implemented. Beginning with the current fiscal year 2025/26 reporting period, the consumer audio segment will be classified as a "discontinued operation held for sale." Full clarity regarding the financial impact of this strategic withdrawal will come on May 18, 2026, when Sonova presents its annual report for the concluded fiscal year. Until then, investors will be monitoring whether the structured divestment process attracts serious buyers promptly and under what terms the exit can be finalized.

Should investors sell immediately? Or is it worth buying Sonova?

Full Concentration on Medical Hearing Solutions

The decision signals a complete retreat from the consumer segment, allowing the group to redirect all its resources and attention back to its core medical competencies. Management's future focus will be exclusively on hearing aids and cochlear implants.

For the roughly 600 employees within the consumer division, including 190 staff at the Hanover site, the announcement initiates a period of uncertainty. However, Sonova has stated that the operational business—encompassing headphones and soundbars—will continue unchanged during the search for a new owner.

A repurchase by the Sennheiser group has been ruled out, as the family-owned enterprise has since specialized in the professional audio sector. Consequently, Sonova must find an external buyer to successfully channel resources back into its medical growth initiatives.

Ad

Sonova Stock: New Analysis - 29 March

Fresh Sonova information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sonova analysis...

CH0012549785 | SONOVA | boerse | 69020696 |